EuroAPI shares at all-time lows after 'weak' H2, disappointing guidance

Euroapi SA

04/03/2026 09:34

** Shares in French drug ingredients maker EuroAPI EAPI.PA drop around 25% to a new all-time low on weakness across results and guidance

** "Weak H2, weak 2026 guide and 2027 earnings target pulled," says Deutsche Bank

** The group reports H2 net loss of 183 million euros ($212 million) and sees 2026 EBITDA margin at 2025 levels of 7.8%, while core EBITDA target for 2027 will not be achieved

** "Sales are now expected below initial assumptions due to increasing competition, mainly from China," says the broker

** EuroAPI anticipates 10% sales decline for 2026

** Portzamparc says management had to review its market assumptions following a "considerable influx of low-cost products" from Asia

** EuroAPI shares have dropped about 33% YTD - LSEG data

($1 = 0.8618 euros)

(Reporting by Dimitri Rhodes in Gdansk)

((dimitri.rhodes@thomsonreuters.com))